Results 201 to 210 of about 269,227 (256)

Adverse Respiratory Reactions to Tyrosine Kinase Inhibitors: A Disproportionality Analysis of Spontaneous Reports from European Countries. [PDF]

Life (Basel)
Ammendolia I, Mannucci C, Esposito E, Calapai G, Currò M, Midiri P, Mondello C, Cancellieri A, Cardia L, Calapai F.   +9 more
europepmc   +1 more source

Evaluating the Safety of Combining Tyrosine Kinase Inhibitors with Anticoagulants in Chronic Myeloid Leukemia: A Systematic Review.

Oncology
Gameil A, Ghasoub R, Jafari N, Shafei L, Benkhadra M, Laws S, Hamad A, Sabet I, Milojkovic D, Fernyhough L.   +9 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Tyrosine Kinase Inhibitors

Current Cancer Drug Targets, 2010
Over the last ten years, several new and therapeutically relevant cancer drugs targeting tyrosine kinases signaling pathways have been developed. Tyrosine kinase inhibitors (TKIs) are a pharmaceutical class of small molecules, orally available, well-tolerated, worldwide approved drugs for the treatment of several neoplasms, including lung, breast ...
NATOLI, Clara, Perrucci Bruno, Perrotti Francesca, Falchi Lorenzo, IACOBELLI, Stefano, Consorzio Interuniversitario Nazionale per Bio Oncologia   +5 more
openaire   +3 more sources

Inhibitors of tyrosine kinase

Current Opinion in Oncology, 1997
This review covers the literature on significant studies of small molecule inhibitors of the epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR), Flk-1, and src family tyrosine kinases from 1996 through mid-1997. During this period, there has been substantial progress in the
W D, Klohs, D W, Fry, A J, Kraker
openaire   +2 more sources

Neoadjuvant Tyrosine Kinase Inhibitors

Thoracic Surgery Clinics
Neoadjuvant tyrosine kinase inhibitor (TKI) therapy has appeal given the potential for early systemic disease control and tumor downstaging prior to surgery. Until recently, data has have come from smaller series with outcomes from larger trials, including NeoADAURA, ALNEO, and NAUTIKA1, reporting early results. Neoadjuvant use of TKI has been shown to
Gavitt A, Woodard, Ryan J, Kramer, Collin M, Blakely   +2 more
openaire   +2 more sources

Tyrosine kinase inhibitors and the thyroid

Best Practice & Research Clinical Endocrinology & Metabolism, 2009
Protein tyrosine kinase inhibitors (TKIs) have emerged as significant targets for novel cancer therapies. For patients with differentiated or medullary carcinomas unresponsive to conventional treatments, multiple novel therapies primarily targeting angiogenesis have entered clinical trials.
openaire   +2 more sources

Inhibitors of protein tyrosine kinases

Current Opinion in Biotechnology, 1995
The description in the past year of several novel protein tyrosine kinase inhibitors, which exhibit dramatic improvements in potency and specificity over earlier agents, will be considered a major turning point in the field. These compounds appear to have the necessary pharmacological properties to finally allow clarification of whether suppression of ...
D W, Fry, A J, Bridges
openaire   +2 more sources

Tyrosine kinase inhibitors

2004
DINSMORE CHRISTOPHER J, BESHORE DOUGLAS C, BERGMAN JEFFREY M, LINDSLEY CRAIG W   +3 more
  +22 more sources

Bruton’s Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials

Molecules, 2023
Anna Krupa, Dariusz Pawlak, Justyna Hermanowicz   +2 more
exaly  

Tyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter?

Cancers, 2021
Imanol Arozarena, Arozarena Imanol
exaly